The correlation between bone biomarkers, glucosylsphingosine levels, and molecular findings in Gaucher type 1 patients under enzyme therapy
Open Access
- 17 March 2022
- journal article
- research article
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (4) , 457-463
Abstract
Objectives: We aimed to determine the relationship of Lyso-Gb1 levels, bone biomarkers, and mutation findings with bone marrow burden (BMB) scores. Methods: Lyso-Gb1 and bone biomarkers, and BMB scores of 10 Gaucher type 1 (GD1) patients under enzyme therapy were prospectively evaluated. Results: Ten GD1 patients, aged between 4.5 and 40 (mean 23 ± 11 years), were included in the study. Four patients were homozygous for L444P/L444P, and six patients were compound heterozygous for N370S/R415H. We found positive correlations between pain and BMB scores with Lyso-Gb1 levels (r=0.889, p=0.001 and r=0.701, p=0.035, respectively). There were negative correlations between bone mineral density (BMD) of both the lumbar spine and femoral neck between Lyso-Gb1 levels (r=−0.929, p=0.001 and r=−0.893, p=0.007, respectively). Patients with L444P/L444P mutation had higher Lyso-Gb1 levels and BMB, pain scores and lower BMD measurements than patients with N370S/R415H (p=0.01, p=0.02, p=0.03, p=0.04, p=0.04, respectively). Conclusions: There was an apparent correlation between, Lyso-Gb1 levels, BMB scores and genotype in evaluating bone involvement in Gaucher patients.Keywords
This publication has 40 references indexed in Scilit:
- Altered innate function of plasmacytoid dendritic cells restored by enzyme replacement therapy in Gaucher diseaseBlood Cells, Molecules, and Diseases, 2013
- Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: A study from the International Collaborative Gaucher Group (ICGG) Gaucher RegistryJournal of Bone and Mineral Research, 2012
- Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic responseBlood, 2011
- Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adultsBlood Cells, Molecules, and Diseases, 2011
- Gaucher disease: a systematic review and meta‐analysis of bone complications and their response to treatmentJournal of Inherited Metabolic Disease, 2010
- Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland ChinaNeuroscience Letters, 2010
- Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort studyClinical Genetics, 2008
- Evidence-based Assessment of Pediatric PainJournal of Pediatric Psychology, 2007
- Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC‐class II: monocytes from Gaucher disease patients as a modelBritish Journal of Haematology, 2005
- Dixon Quantitative Chemical Shift Imaging Is a Sensitive Tool for the Evaluation of Bone Marrow Responses to Individualized Doses of Enzyme Supplementation Therapy in Type 1 Gaucher DiseaseBlood Cells, Molecules, and Diseases, 2001